🧬Just published!Our study reveals MTTP I128T reduces hepatic steatosis AND plasma lipids.Promising target to reduce hepatic and circulating lipids! @KM_Schneider1 @ktc_phd @VujkovicM @HelenYRHuang @EScorletti @inukzand @UniklinikAachen @APandT bit.ly/43s2s6u (1/5)
Not only did carriers of the MTTP I128T variant have less hepatic steatosis, but they also showed lower plasma lipids, including LDL-cholesterol and apoB in two independent cohorts. 📉 This unexpected association opens new possibilities for lipid-lowering therapies. (3/5) #mttp
Functional studies revealed that MTTP I128T is neither a typical loss nor gain of function allele. This suggests a more complex effect on MTTP activity, potentially involving a novel mechanism yet to be uncovered. 🧬🔍 #FunctionalGenomics #MolecularMechanisms (4/5)
Our findings indicate that targeting the MTTP I128T variant could be a promising strategy for reducing hepatic and circulating lipids, offering potential therapeutic avenues. 🎯🔬 Stay tuned for further investigations on this intriguing variant! #FutureTherapies #Research (5/5)
Thanks to all participants of @uk_biobank and @PennMedEVDCSO Biobank.